These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 16636629)

  • 1. Current status of augmentation and combination treatments for major depressive disorder: a literature review and a proposal for a novel approach to improve practice.
    Fava M; Rush AJ
    Psychother Psychosom; 2006; 75(3):139-53. PubMed ID: 16636629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Residual symptoms after a treated major depressive disorder: in practice ambulatory observatory carried out of city].
    Mouchabac S; Ferreri M; Cabanac F; Bitton M
    Encephale; 2003; 29(5):438-44. PubMed ID: 14615693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mood stabilizer augmentation in apparently "unipolar" MDD: predictors of response in the naturalistic French national EPIDEP study.
    Hantouche EG; Akiskal HS; Lancrenon S; Chatenêt-Duchêne L
    J Affect Disord; 2005 Feb; 84(2-3):243-9. PubMed ID: 15708422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treating depression after initial treatment failure: directly comparing switch and augmenting strategies in STAR*D.
    Gaynes BN; Dusetzina SB; Ellis AR; Hansen RA; Farley JF; Miller WC; Stürmer T
    J Clin Psychopharmacol; 2012 Feb; 32(1):114-9. PubMed ID: 22198447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternative approaches to refractory depression in bipolar illness.
    Post RM; Leverich GS; Denicoff KD; Frye MA; Kimbrell TA; Dunn R
    Depress Anxiety; 1997; 5(4):175-89. PubMed ID: 9338110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice.
    Goodwin G; Fleischhacker W; Arango C; Baumann P; Davidson M; de Hert M; Falkai P; Kapur S; Leucht S; Licht R; Naber D; O'Keane V; Papakostas G; Vieta E; Zohar J
    Eur Neuropsychopharmacol; 2009 Jul; 19(7):520-32. PubMed ID: 19411165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Augmenting antidepressants with folate: a clinical perspective.
    Fava M
    J Clin Psychiatry; 2007; 68 Suppl 10():4-7. PubMed ID: 17900202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A primary care focus on the diagnosis and treatment of major depressive disorder in adults.
    Halaris A
    J Psychiatr Pract; 2011 Sep; 17(5):340-50. PubMed ID: 21926529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Achieving remission and managing relapse in depression.
    Thase ME
    J Clin Psychiatry; 2003; 64 Suppl 18():3-7. PubMed ID: 14700448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Agitated "unipolar" depression re-conceptualized as a depressive mixed state: implications for the antidepressant-suicide controversy.
    Akiskal HS; Benazzi F; Perugi G; Rihmer Z
    J Affect Disord; 2005 Apr; 85(3):245-58. PubMed ID: 15780694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Augmentation of antidepressants with perospirone for treatment-resistant major depressive disorder.
    Sato Y; Yasui-Furukori N; Nakagami T; Saito M; Kaneko S
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Apr; 33(3):416-8. PubMed ID: 19166896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinician perspective on achieving and maintaining remission in depression.
    Kelsey JE
    J Clin Psychiatry; 2001; 62 Suppl 26():16-21. PubMed ID: 11775088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment-resistant depression: prevalence, risk factors, and treatment strategies.
    Thase ME
    J Clin Psychiatry; 2011 May; 72(5):e18. PubMed ID: 21658343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Residual symptoms and recurrence in major depressive disorder].
    Spadone C; Corruble E
    Encephale; 2010 Dec; 36 Suppl 5():S108-11. PubMed ID: 21211628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Severe depression : pharmacological treatments].
    Mouchabac S
    Encephale; 2009 Dec; 35 Suppl 7():S319-24. PubMed ID: 20141796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medication use patterns and two-year outcome in first-admission patients with major depressive disorder with psychotic features.
    Craig TJ; Grossman S; Bromet EJ; Fochtmann LJ; Carlson GA
    Compr Psychiatry; 2007; 48(6):497-503. PubMed ID: 17954133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Augmentation and combination strategies for depression.
    DeBattista C
    J Psychopharmacol; 2006 May; 20(3 Suppl):11-8. PubMed ID: 16644767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. II. Psychotherapy alone or in combination with antidepressant medication.
    Parikh SV; Segal ZV; Grigoriadis S; Ravindran AV; Kennedy SH; Lam RW; Patten SB;
    J Affect Disord; 2009 Oct; 117 Suppl 1():S15-25. PubMed ID: 19682749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using adjunctive treatments when first-line antidepressants fail.
    Thase ME
    J Clin Psychiatry; 2012 Jan; 73(1):e01. PubMed ID: 22316580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Major depressive disorder treatment guidelines in America and Europe.
    Davidson JR
    J Clin Psychiatry; 2010; 71 Suppl E1():e04. PubMed ID: 20371031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.